Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
afatanib, announced, Ariad, ARIEL, assessed, Assessment, August, BID, biomarker, BRCA, breast, British, chemotherapy, cohort, confer, Conference, dacomitinib, daily, DNA, dose, dosed, dosing, driven, durable, escalation, evidence, free, germline, Gilotrif, half, Hanmi, HBr, hydrobromide, maximum, mg, October, olaprib, ovarian, PCR, Pharmacokinetic, placebo, platinum, PR, pretreated, PRs, QIAGEN, randomized, RECIST, RGQ, sequencing, shown, shrinkage, skin, stable, Taiho, thetherascreen, toxicity, tumor
Filing tables
Filing exhibits
Related press release
CLVSQ similar filings
Filing view
External links